Economic Analysis of Health Policy
Analyzing Impact of Healthcare Programs on Social and Economic Development of the Country
Evidence of cost-effectiveness or an acceptable budget impact of a specific medication allows promoting it through existing channels of drug supply. However, if such channels are not fully functional due to insufficient funding, the ability to promote drugs using traditional HEOR methods is limited. In such cases, additional arguments are needed to justify creating new or significantly expanding existing access channels for drugs in the market, for example, launching a new program to combat a certain disease.
Forecasting the social burden of HIV until 2030 based on population mortality criteria.
Economic analysis of health policy may be used to support launch of such programs. For example, it is possible to model how the burden of a disease will change under different scenarios of government policies to combat it.
Such studies are particularly significant in situations where there are effective methods of drug therapy aimed at controlling or curing the disease. Then, the increase in medication costs can be compensated by a decrease in other categories of expenses. It is also possible to demonstrate other important effects for the state and society from expanding access to pharmaceuticals, such as increased life expectancy or increased birth rates.
Thus, additional funding for drug procurements can be positioned as investments in reducing other losses, rather than irrevocable costs.
Such studies are particularly significant in situations where there are effective methods of drug therapy aimed at controlling or curing the disease. Then, the increase in medication costs can be compensated by a decrease in other categories of expenses. It is also possible to demonstrate other important effects for the state and society from expanding access to pharmaceuticals, such as increased life expectancy or increased birth rates.
Thus, additional funding for drug procurements can be positioned as investments in reducing other losses, rather than irrevocable costs.
Forecasting the economic burden of HIV until 2030.
Our team has extensive experience in conducting economic analysis of health policy,examining the effects of expanding access to drugs for the treatment of HIV infection, chronic hepatitis C, and several severe life-threatening orphan diseases. The results of our work are actively covered in the media and find a response among key decision-makers in healthcare in Russia.
We are open to new projects in the field of economic analysis of various health programs. If your company needs to emphasize the importance of measures to combat a particular disease, please contact us and we will make every effort to solve your problems!
We are open to new projects in the field of economic analysis of various health programs. If your company needs to emphasize the importance of measures to combat a particular disease, please contact us and we will make every effort to solve your problems!
Selected publications
Economic Analysis of Health Policy
Contact us
Email: info@pharmanalytics.me
United Arab Emirates, Ras Al Khaimah, Al Hulaila Industrial Zone-FZ, Shed No.23, W6_SO15
United Arab Emirates, Ras Al Khaimah, Al Hulaila Industrial Zone-FZ, Shed No.23, W6_SO15
